Sign in

DGX on NYSE

Quest Diagnostics

American clinical laboratory company

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.3 It was founded by Paul A. Brown.1 Its chief executive is Steve Rusckowski.1 Its revenue was $9.9 billion in 2022.1 Its shares trade on NYSE under the symbol DGX.1 Wikipedia text CC BY-SA 4.0

$234.83 down 4.32 (1.81%)Price as of Oct 16, 2026 at 19:58 UTC

Last updated Oct 21, 2026.

Overview

1967Founded1

Compare with LabCorp, Exact Sciences or Fortrea Holdings Inc., or pick any stock.

  • TickerDGX on NYSE1
  • Industryhealth care1
  • HeadquartersMadison1
  • Founded inNew York City1
  • Websitewww.questdiagnostics.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address500 Plaza Drive, Secaucus, Nj 070946
  • Filer categoryLarge accelerated filer6
  • LEI8MCWUBXQ0WE04KMXBX504
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 22490884

See how the biggest companies compare on our leaderboards

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

14.1%Operating margin9
9.0%Net margin9
11.8%Revenue growth, 20259
13.8%Return on equity9
0.72×Debt to equity9
$1.4BFree cash flow9

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Diagnostic Information Services Business brought in 98% of the revenue Quest Diagnostics broke down this way in fiscal 2025.

  1. Diagnostic Information Services Business$10.8B998%up 12% from 2024
  2. Other Operating$250.0M92%down 3% from 2024
Business segments by year
Business segments202320242025
Diagnostic Information Services Business$9.0B$9.6B$10.8B
Other Operating$276.0M$258.0M$250.0M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue67¢$7.4B
  • Selling, general and admin18¢$2.0B
  • Other costs4¢$392.0M
  • Income tax3¢$314.0M
  • Profit9¢$992.0M

Out of $11.0B in revenue.9

Where each dollar of operating cash went, fiscal 2025

  • Capital spending28¢$527.0M
  • Dividends paid19¢$353.0M
  • Share buybacks24¢$450.0M
  • Kept or used elsewhere29¢$556.0M

Out of $1.9B of cash from operations.9

Financial statements

Revenue101112139$11.0B in 2025+43% since 2019
0$5.0B$10.0B$15.0B2019: $7.7B$7.7B20192020: $9.4B$9.4B2020+22%2021: $10.8B$10.8B2021+14%2022: $9.9B$9.9B2022−8%2023: $9.3B$9.3B2023−6%2024: $9.9B$9.9B2024+7%2025: $11.0B$11.0B2025+12%
Gross profit14$3.6B in 2020+35% since 2019
0$1.0B$2.0B$3.0B$4.0B2019: $2.7B$2.7B20192020: $3.6B$3.6B2020+35%
Operating income101112139$1.6B in 2025+26% since 2019
0$1.0B$2.0B$3.0B2019: $1.2B$1.2B20192020: $2.0B$2.0B2020+60%2021: $2.4B$2.4B2021+21%2022: $1.4B$1.4B2022−40%2023: $1.3B$1.3B2023−12%2024: $1.3B$1.3B2024+7%2025: $1.6B$1.6B2025+16%
Net income101112139$992.0M in 2025+16% since 2019
0$500.0M$1.0B$1.5B$2.0B2019: $858.0M$858.0M20192020: $1.4B$1.4B2020+67%2021: $2.0B$2.0B2021+39%2022: $946.0M$946.0M2022−53%2023: $854.0M$854.0M2023−10%2024: $871.0M$871.0M2024+2%2025: $992.0M$992.0M2025+14%

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
Net revenues$11.0B$9.9B$9.3B
Cost of services$7.4B$6.6B$6.2B
Selling, general and administrative$2.0B$1.8B$1.6B
Amortization of intangible assets$154.0M$127.0M$108.0M
Other operating (income) expense, net-$12.0M$1.0M$41.0M
Total operating costs and expenses, net$9.5B$8.5B$8.0B
Operating income$1.6B$1.3B$1.3B
Interest expense, net-$264.0M-$201.0M-$152.0M
Other Nonoperating Income (Expense)$26.0M$30.0M$20.0M
Total non-operating expense, net-$238.0M-$171.0M-$132.0M
Income before income taxes and equity in earnings of equity method investees$1.3B$1.2B$1.1B
Income tax expense-$314.0M-$273.0M-$248.0M
Equity in earnings of equity method investees, net of taxes$42.0M$19.0M$26.0M
Net income$1.0B$921.0M$908.0M
Less: Net income attributable to noncontrolling interests$54.0M$50.0M$54.0M
Net income attributable to Quest Diagnostics$992.0M$871.0M$854.0M
Basic (in dollars per share)$8.87$7.78$7.59
Diluted (in dollars per share)$8.75$7.69$7.49

Compare Quest Diagnostics with another company

Corporate structure

Quest Diagnostics sits at the top of its group. 31 entities, 9 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Quest Diagnostics

  • Quest Diagnostics Secaucus, New Jersey, United States
    • Celera Corporation Subsidiary · Alameda
    • Blueprint Genetics Oy Subsidiary · 100% · Espoo, Finland
    • QUEST DIAGNOSTICS INDIA PRIVATE LIMITED Subsidiary · 99.99% · Gurgaon, India
    • 100% AmeriPath Subsidiary · Florida, United States
    • 100% AmeriPath Hospital Services Subsidiary · Florida, United States
    • 100% AmeriPath Tucson, Inc. (AZ) AmeriPath Subsidiary · Arizona, United States
    • 100% Blueprint Genetics Oy Subsidiary · Finland
    • 100% Diagnostic Pathology Services, Inc. (OK) AmeriPath Subsidiary · Oklahoma, United States
    • 100% ExamOne Canada, Inc. Subsidiary · New Brunswick, Canada
    • 100% Haystactack Oncology GmbH Subsidiary · Germany
    • 100% Lab One of Subsidiary · Ohio, United States
    • 100% LifeLabs GP ULC Subsidiary · Ontario, Canada
    • 100% Quest Diagnostics (Shanghai) Co., Ltd. Subsidiary · China
    • 100% Quest Diagnostics do Brasil Ltda. Subsidiary · Brazil
    • 100% Quest Diagnostics Holdings Ltd. Subsidiary · United Kingdom
    • 100% Quest Diagnostics India Private Limited Subsidiary · India
    • 100% Quest Diagnostics International Holdings Limited Subsidiary · United Kingdom
    • 100% Quest Diagnostics Ireland Limited Subsidiary · Ireland
    • 100% Quest Diagnostics of Puerto Rico, Inc. Subsidiary · Puerto Rico, United States
    • 53.5% Associated Clinical Laboratories of Subsidiary · Pennsylvania, United States
    • AmeriPath Central Subsidiary · Florida, United States
    • AmeriPath North Subsidiary · Texas, United States
    • AmeriPath South Subsidiary · Florida, United States
    • Dermpath Diagnostics Subsidiary · Texas, United States
    • Institute, Inc. of Subsidiary · Virginia, United States
    • and 5 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Quest Diagnostics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$6.2B9 Dec 31, 2025$5.8B9 Dec 31, 2024+7.0%
Accumulated depreciation$4.0B9 Dec 31, 2025$3.7B9 Dec 31, 2024+8.6%
Property and equipment, net$2.2B9 Dec 31, 2025$2.1B9 Dec 31, 2024+4.3%
Finance-lease assets$20.0M9 Dec 31, 2025$17.0M9 Dec 31, 2024+17.6%
Operating-lease assets (leased space)$657.0M9 Dec 31, 2025$651.0M9 Dec 31, 2024+0.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$420.0M9 Dec 31, 2025$549.0M9 Dec 31, 2024−23.5%
Debt securities available for sale$09 Dec 31, 2025$09 Dec 31, 2024
Stakes in other companies (equity method)$136.0M9 Dec 31, 2025$123.0M9 Dec 31, 2024+10.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$8.9B9 Dec 31, 2025$8.9B9 Dec 31, 2024+1.0%
Intangible assets, net (excluding goodwill)$1.6B9 Dec 31, 2025$1.8B9 Dec 31, 2024−7.2%
Accumulated amortization$1.3B9 Dec 31, 2025$1.3B9 Dec 31, 2024+7.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$189.0M9 Dec 31, 2025$188.0M9 Dec 31, 2024+0.5%

Properties, in its own words

Our executive offices are located at 500 Plaza Drive, Secaucus, New Jersey. We maintain clinical testing laboratories throughout the continental United States; in several instances a joint venture of which we are a partner maintains the laboratory. We also maintain offices, data centers, call centers, distribution centers and patient service centers at locations throughout the United States. In addition, we maintain offices, patient service centers and clinical laboratories in locations outside the United States, including in Canada, Finland, Puerto Rico and Mexico. Our properties that are not owned are leased on terms and for durations that are reflective of commercial standards in the communities where these properties are located. We believe that, in general, our facilities are suitable and adequate for our current and anticipated future levels of operation and are adequately maintained. We believe that if we were unable to renew a lease on any of our facilities, we could find alternative space at competitive market rates and relocate our operations to such new location without material disruption to our business. Several of our principal facilities are highlighted below.

Location · Leased or Owned

The rest of Item 2

3600 Northgate Blvd., Sacramento, California 95834 (laboratory) · Leased

8401 Fallbrook Avenue, West Hills, California 91304 (laboratory) · Leased

33608 Ortega Hwy., San Juan Capistrano, California 92675 (laboratory) · Owned

4151C East Fowler Avenue, Tampa, Florida 33617 (laboratory) · Owned

1777 Montreal Circle, Tucker, Georgia 30084-6802 (laboratory) · Owned

506 E State Parkway, Schaumburg, Illinois 60173 (laboratory) · Owned

1355 Mittle Blvd., Wood Dale, Illinois 60191 (laboratory) · Leased

200 Forest Street, Marlborough, Massachusetts 01752 (laboratories) · Leased

4770 Regent Blvd., Irving, Texas 75063 (laboratory) · Leased

14225 Newbrook Drive, Chantilly, Virginia 22021 (laboratory) · Leased

10101 Renner Blvd., Lenexa, Kansas 66219 (laboratory) · Owned

4380 Federal Drive, Greensboro, North Carolina 27410 (laboratory) · Leased

2501 South State Hwy 121, Lewisville, Texas 75067 (laboratory) · Leased

6700 Euclid Avenue, Cleveland, Ohio 44103 (laboratory) · Leased

One Insights Drive, Clifton, NJ 07012 (laboratory) · Owned

100 International Boulevard, Toronto, Ontario, M9W 6J6, Canada (laboratory) · Owned

3680 Gilmore Way Burnaby, British Columbia, Canada (laboratory) · Owned

6560 Kennedy Road, Mississauga, Ontario, L5T 2X4, Canada (laboratory) · Leased

Item 2 of the 10-K filed Feb 26, 2026.17

The story

Founded by Paul A. Brown in 1967, in New York City.1

1960–1995

Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.

1996–2000

On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.

In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.

2001–2015

From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.

2016–present

In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.

By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.

In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.

In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.

Read the full text

In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.

In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.

In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.

In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.

From Wikipedia’s article on Quest Diagnostics, shared under CC BY-SA 4.0.7

Leadership

Who has led Quest Diagnostics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Surya N. Mohapatra2006–2012
  2. Steve Rusckowski2012–2022
  3. J. E. Davis2022–now

Chair

  1. Surya N. Mohapatra2006–2012
  2. Steve Rusckowski2017–2022

President

  1. Surya N. Mohapatra2006–2012
  2. Steve Rusckowski2012–2022
  3. J. E. Davis2022–now

Chief financial officer

  1. Robert Hagemann2006–2013
  2. Mark Guinan2013–2022
  3. Samer Abdul Samad2022–now
197019801990200020102020
Board members and other officers (43)

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • 100% AmeriPath Florida, LLC (DE)8
  • 100% AmeriPath Hospital Services Florida, LLC (DE)8
  • 100% AmeriPath Tucson, Inc. (AZ) AmeriPath Arizona8
  • 100% Blueprint Genetics Oy Finland8
  • 100% Diagnostic Pathology Services, Inc. (OK) AmeriPath Oklahoma8
  • 100% ExamOne Canada, Inc. New Brunswick, Canada8
  • 100% Haystactack Oncology GmbH Germany8
  • 100% Lab One of Ohio, Inc. (DE)8
  • 100% LifeLabs GP ULC Ontario, Canada8
  • 100% Quest Diagnostics (Shanghai) Co., Ltd. China8
  • 100% Quest Diagnostics Holdings Ltd. UK8
  • 100% Quest Diagnostics India Private Limited India8
  • 100% Quest Diagnostics International Holdings Limited UK8
  • 100% Quest Diagnostics Ireland Limited Ireland8
  • 100% Quest Diagnostics do Brasil Ltda. Brazil8
  • 100% Quest Diagnostics of Puerto Rico, Inc. Puerto Rico8
  • 53.5% Associated Clinical Laboratories of Pennsylvania, L.L.C. (PA)8
  • AmeriPath Central Florida8
  • AmeriPath North Texas8
  • AmeriPath South Florida8
  • Dermpath Diagnostics Texas8
  • Institute, Inc. of Virginia8
  • LabOne, LLC of Kansas8
  • Pathology Associates of Texas8
All 25 listed subsidiaries
  • Quest Diagnostics Incorporated of Nevada8

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

Partnerships

2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.

From Wikipedia’s article on Quest Diagnostics, shared under CC BY-SA 4.0.7

Former names

  • CORNING CLINICAL LABORATORIES INCDec 13, 1996 to Mar 19, 19976

Timeline

  1. Oct 6, 20268-K Executive or director change67
  2. Jul 23, 20268-K Results of operations68
  3. May 21, 20268-K Shareholder vote69
  4. May 8, 20268-K Entered a material agreement70
  5. May 1, 20268-K Other events71
  6. Apr 21, 20268-K Results of operations72
  7. Mar 12, 20268-K Executive or director change; Regulation FD disclosure73
  8. Feb 10, 20268-K Results of operations; Other events74
  9. Jan 12, 20268-K Results of operations; Regulation FD disclosure75
  10. Oct 21, 20258-K Results of operations76
  11. Jul 22, 20258-K Results of operations77
  12. May 22, 20258-K Shareholder vote78
  13. Feb 25, 2022New chief executive J. E. Davis becomes CEO18
  14. May 2, 2012New chief executive Steve Rusckowski becomes CEO1
  15. Feb 17, 2006New chief executive Surya N. Mohapatra becomes CEO20
  16. Dec 26, 1996Went public Listed on NYSE1
  17. 1967Founded Founded in New York City1

Calendar

Coming up

  1. Oct 22, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $2.60 a share, on Oct 21, 2025.79

When it reported results

  1. Jul 23, 2026Reported quarterly or annual results68
  2. Apr 21, 2026Reported quarterly or annual results72
  3. Feb 10, 2026Reported quarterly or annual results74
  4. Jan 12, 2026Reported quarterly or annual results75
  5. Oct 21, 2025Reported quarterly or annual results76
  6. Jul 22, 2025Reported quarterly or annual results77
  7. Apr 22, 2025Reported quarterly or annual results80
  8. Jan 30, 2025Reported quarterly or annual results81

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

529 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 347 insider forms, 17 large holders, 92 other. The latest 20:

  1. Oct 6, 20268-K CURRENT REPORT EDGAR
  2. Oct 2, 20264 EDGAR
  3. Sep 3, 20264 EDGAR
  4. Sep 1, 2026144 EDGAR
  5. Aug 31, 20264 EDGAR
  6. Aug 28, 2026144 EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Jul 29, 20264 EDGAR
  9. Jul 28, 2026144 EDGAR
  10. Jul 27, 20264 EDGAR
  11. Jul 27, 20264 EDGAR
  12. Jul 27, 20264 EDGAR
  13. Jul 27, 20264 EDGAR
  14. Jul 27, 20264 EDGAR
  15. Jul 27, 20264 EDGAR
  16. Jul 27, 20264 EDGAR
  17. Jul 27, 20264 EDGAR
  18. Jul 23, 202610-Q EDGAR
  19. Jul 23, 20268-K EDGAR
  20. Jul 2, 20264 EDGAR

The 529 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

85 open-market trades by officers, directors and large owners since October 2021: 0 buys and 85 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 1, 2026Davis J. E.CEO and PresidentSale10,000$242.72$2.4MForm 4
Aug 28, 2026PREVOZNIK MICHAEL ESVP & General CounselSale22,677$243.12$5.5MForm 4
Jul 28, 2026DELANEY MARK ESVP & Chief Commercial OfficerSale1,600$235.18$376.3KForm 4
Jun 4, 2026KUPPUSAMY KARTHIKSVP, Clinical SolutionsSale8,147$200.00$1.6MForm 4
Jun 1, 2026Davis J. E.CEO and PresidentSale10,000$194.14$1.9MForm 4
Mar 5, 2026Doherty Catherine T.EVP, Regional BusinessesSale5,558$206.21$1.1MForm 4
Mar 5, 2026PREVOZNIK MICHAEL ESVP & General CounselSale3,878$206.21$799.7KForm 4
Mar 5, 2026Plewman PatrickSVP for Diagnostic ServicesSale2,855$206.21$588.7KForm 4
Mar 4, 2026KUPPUSAMY KARTHIKSVP, Clinical SolutionsSale2,628$204.86$538.4KForm 4
Mar 3, 2026Doherty Catherine T.EVP, Regional BusinessesSale632$207.73$131.3KForm 4
Mar 3, 2026PREVOZNIK MICHAEL ESVP & General CounselSale526$207.73$109.3KForm 4
Mar 3, 2026Plewman PatrickSVP for Diagnostic ServicesSale410$207.73$85.2KForm 4
Mar 2, 2026Davis J. E.CEO and PresidentSale10,000$212.52$2.1MForm 4
Feb 19, 2026Doherty Catherine T.EVP, Regional BusinessesSale1,433$204.83$293.5KForm 4
Feb 19, 2026Plewman PatrickSVP for Diagnostic ServicesSale958$204.83$196.2KForm 4
Feb 19, 2026PREVOZNIK MICHAEL ESVP & General CounselSale1,111$204.83$227.6KForm 4
Feb 13, 2026Doherty Catherine T.EVP, Regional BusinessesSale26,165$206.15$5.4MForm 4
Feb 10, 2026Plewman PatrickSVP for Diagnostic ServicesSale5,662$204.00$1.2MForm 4
Nov 25, 2025Davis J. E.CEO and PresidentSale55,093$192.22$10.6MForm 4
Nov 25, 2025Gregg Vicky BDirectorSale1,250$191.76$239.7KForm 4

All 85 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025James E. DavisChairman, Chief Executive Officer and President63$1.2M$15.5M88
2025Sam A. SamadExecutive Vice President and Chief Financial Officer$693.3K$4.4M88
2025Catherine T. DohertyExecutive Vice President, Regional Businesses$643.3K$3.6M88
2025Karthik KuppusamySenior Vice President, Clinical Solutions$568.3K$2.6M88
2025Michael E. PrevoznikSenior Vice President and General Counsel$550.0K$2.6M88
2024James E. DavisChairman, Chief Executive Officer and President63$1.2M$14.4M88
2024Sam A. SamadExecutive Vice President and Chief Financial Officer$668.3K$4.1M88
2024Catherine T. DohertyExecutive Vice President, Regional Businesses$618.3K$3.3M88
2024Michael E. PrevoznikSenior Vice President and General Counsel$550.0K$2.4M88
2024Karthik KuppusamySenior Vice President, Clinical Solutions$543.3K$2.3M88
2023James E. DavisChairman, Chief Executive Officer and President63$1.2M$12.7M88
2023Sam A. SamadExecutive Vice President and Chief Financial Officer$650.0K$4.0M88
2023Catherine T. DohertyExecutive Vice President, Regional Businesses$600.0K$3.2M88
2023Michael E. PrevoznikSenior Vice President and General Counsel$542.5K$2.3M88
2023Karthik KuppusamySenior Vice President, Clinical Solutions$512.5K$2.0M88

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.9,275,411$2.0B0.0%+103,119
Vanguard Capital Management LLC7,233,394$1.5B0.0%+87,722
Vanguard Portfolio Management LLC6,131,045$1.3B0.1%+49,645
State Street Corp5,516,643$1.2B0.0%+135,822
Boston Partners4,744,473$1.0B0.9%+732,241
Jpmorgan Chase & Co3,520,438$748.6M0.0%−326,018
Geode Capital Management, LLC3,137,873$662.6M0.0%+51,565
Morgan Stanley2,460,497$521.5M0.0%−19,223
EdgePoint Investment Group Inc.2,247,568$476.4M3.6%+3,699
Dimensional Fund Advisors LP1,988,048$421.4M0.1%+38,513
Bank Of America Corp /de/1,935,133$410.2M0.0%+182,231
Grantham, Mayo, Van Otterloo & Co. LLC1,888,207$400.2M0.9%+5,183
Wells Fargo & Company/mn1,751,220$371.2M0.1%−11,549
Davis Selected Advisers1,555,612$329.8M1.4%−62,201
Victory Capital Management Inc1,550,556$328.6M0.2%−295,780
Norges Bank1,406,620$298.1M0.0%New
Fmr LLC1,398,735$296.5M0.0%+456,517
Invesco Ltd.1,379,115$292.3M0.0%−259,372
Northern Trust Corp1,127,454$239.0M0.0%+13,235
Goldman Sachs Group Inc982,694$208.3M0.0%−366,000
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC942,407$199.7M0.0%+95,804
UBS Group AG888,906$188.4M0.0%+186,569
American Century Companies Inc818,220$173.4M0.1%−49,111
M&g PLC795,650$168.7M0.9%−9,691
Charles Schwab Investment Management Inc773,711$164.0M0.0%+12,921

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

22 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 30, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000−2.9%Report
Mar 27, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000−1.5%Report
Nov 3, 2025Julie JohnsonDemocratic, HouseSale$1,001 - $15,000−18.5%Report
Oct 30, 2025Julie JohnsonDemocratic, HouseBuy$1,001 - $15,000+20.2%Report
Oct 30, 2025Julie JohnsonDemocratic, HouseSale$1,001 - $15,000−20.2%Report
Jul 24, 2025Julia LetlowRepublican, HouseSale$1,001 - $15,000−15.1%Report
Apr 28, 2025Julia LetlowRepublican, HouseBuy$1,001 - $15,000−7.1%Report
Mar 10, 2025Carol D. MillerRepublican, HouseSale$15,001 - $50,000+1.9%Report
Mar 10, 2025Carol D. MillerRepublican, HouseSale$1,001 - $15,000+1.9%Report
Apr 4, 2024Earl Blumenauer, HouseSale$1,001 - $15,000−28.3%Report
Jan 3, 2024Tommy TubervilleRepublican, SenatePartial sale$15,001 - $50,000−3.6%Report
Dec 11, 2023Thomas R Carper, SenatePartial sale$1,001 - $15,000−4.6%Report
Nov 14, 2022Carol D. MillerRepublican, HouseBuy$1,001 - $15,000−39.1%Report
Aug 3, 2022Kathy Manning, HouseSale$1,001 - $15,000+15.8%Report
Jul 20, 2022Kathy Manning, HouseBuy$1,001 - $15,000−21.2%Report
Jul 28, 2021Carol D. MillerRepublican, HouseBuy$15,001 - $50,000−8.0%Report
Mar 29, 2021Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−11.5%Report
Apr 2, 2020Dean Phillips, HousePartial sale$1,001 - $15,000+3.1%Report
Apr 2, 2020Thomas R Carper, SenateBuy$1,001 - $15,000−3.1%Report
Mar 2, 2020Earl Blumenauer, HouseBuy$1,001 - $15,000−40.1%Report
Feb 10, 2020Dean Phillips, HousePartial sale$1,001 - $15,000+20.1%Report
Jan 17, 2020Dean Phillips, HouseBuy$1,001 - $15,000−13.0%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Quest Diagnostics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARQUEST DIAGNOSTICS INC2
  • CIK0001022079
  • Employer ID (EIN)16-138786217
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
  • Incorporated inDelaware17
  • Fiscal year endsDecember 312
  • Industry code (SIC)8071 Services-Medical Laboratories2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address500 Plaza Drive, Secaucus, NJ 070942
  • Phone97352027002
  • Shares outstanding110,373,360 as of Jul 15, 202616
  • Public float$20.0B as of Jun 30, 202517
  • AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey PCAOB ID 238; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceSep 23, 19962
  • Filings2,397 in all: 4 (1,396), 8-K (292), 10-Q (89), SC 13G/A (66), 144 (60), SC TO-T/A (41), 3 (37), 11-K (33)2
    All 58 form types

    425 (32), DEF 14A (29), 10-K (28), S-8 (22), SC 13G (22), DEFA14A (21), UPLOAD (20), 424B2 (19), SC 13D/A (15), 4/A (13), 8-K/A (13), CORRESP (13), FWP (13), 424B3 (10), ARS (10), S-8 POS (9), S-3/A (8), PRE 14A (7), S-3ASR (7), CT ORDER (5), SC 13D (5), 10-12B/A (4), S-3 (4), S-4/A (4), SCHEDULE 13G/A (4), 3/A (3), NO ACT (3), POSASR (3), PX14A6G (3), S-1/A (3), SC 13E3/A (3), SCHEDULE 13G (3), 10-K/A (2), 10-K405 (2), 424B5 (2), 5 (2), S-4 (2), SC 13E3 (2), SC TO-T (2), 10-12B (1), 15-15D (1), 25 (1), 25-NSE (1), 424B4 (1), 424B7 (1), 8-A12B (1), 8-A12B/A (1), DEFR14A (1), POS AM (1), SD (1)

  • Latest filingsAnnual report (10-K) Feb 26, 2026
    Quarterly report (10-Q) Jul 23, 2026
    Proxy statement (DEF 14A) Apr 6, 2026
    Latest 8-K (8-K) Oct 6, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $.01 par valueDGXNew York Stock Exchange

From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks Quest Diagnostics names in Item 1A of its 10-K filed Feb 26, 2026: 26 risks under these headings, as written.17

  • RISKS RELATED TO OUR BUSINESS
  • The U.S. healthcare system continues to evolve, and medical laboratory testing market fundamentals are changing, and our business could be adversely impacted if we fail to adapt.
  • The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability.
  • Government payers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services.
  • Health plans and other third parties have taken steps to reduce the utilization and reimbursement of health services, including clinical testing services.
  • Failure to develop, acquire licenses for, introduce, or commercialize new tests, technology and services could negatively impact our testing volume, revenues and profitability.
  • Failure to establish, and perform to, appropriate quality standards, or to assure that the appropriate standard of quality is observed in the performance of our diagnostic information services, could adversely affect the results of our operations and adversely impact our reputation.
  • RISKS RELATED TO CHANGE IN PUBLIC POLICY
  • Significant changes or developments in U.S. laws or policies, including changes in U.S. healthcare regulation, may have a material adverse effect on our business.
  • We are subject to numerous legal and regulatory requirements governing our activities, and we may face substantial fines and penalties, and our business activities may be impacted, if we fail to comply.
  • Our business and operations could be adversely impacted by the FDA's approach to regulation.
  • Failure to accurately bill for our services, or to comply with applicable laws relating to billing government healthcare programs, could have a material adverse effect on our business.
The other 16 risks
  • We are subject to numerous political (including geopolitical), legal, operational and other risks as a result of our international operations which could impact our business in many ways.
  • We may be unable to obtain, maintain or enforce our intellectual property rights and may be subject to intellectual property litigation that could adversely impact our business.
  • Adverse results in material litigation could have an adverse financial impact and an adverse impact on our client base and reputation.
  • RISKS RELATED TO OUR INDEBTEDNESS
  • Our outstanding debt may impair our financial and operating flexibility.
  • RISKS RELATED TO OUR OPERATIONS
  • The development of new technologies is rapidly changing diagnostic testing, which will impact the healthcare industry and the competitive environment. The development of new, more cost-effective solutions that can be performed by our customers or by patients, which could accelerate the internalization of testing by hospitals or clinicians, could negatively impact our testing volume and revenues.
  • We have been and expect to continue to use AI technology in the testing services we offer. The challenges with properly managing the development and use of these technological innovations could result in harm to our reputation, business or customers, and adversely affect our results of operations.
  • Hardware and software failures or delays in our IT systems, including failures resulting from our systems conversions, services and support provided by third parties, or otherwise, could disrupt our operations and cause the loss of confidential information, customers and business opportunities or otherwise adversely impact our business.
  • Our business could be negatively affected if we are unable to continue to strengthen our efficiency.
  • Our business operations and reputation may be materially impaired if we do not comply with privacy laws or information security policies.
  • Our approach to corporate responsibility may not satisfy all our stakeholders.
  • The IT systems that we rely on may be subject to unauthorized tampering, cyberattack or other security breach.
  • Our ability to attract and retain qualified employees and maintain good relations with our employees is critical to the success of our business and the failure to do so may materially adversely affect our performance.
  • Business development activities are inherently risky and integrating our operations with businesses we acquire may be difficult.
  • Our operations may be adversely impacted by the effects of natural disasters such as hurricanes and earthquakes, public health emergencies and pandemics, geopolitical conflicts, hostilities or acts of terrorism and other criminal activities.
  • Any future public health emergencies or pandemics may negatively affect us, including through its impact on the labor force and supply chain.
  • Inflationary pressures could adversely impact us because of increases in the costs of materials, supplies and services, and increased labor and people-related expenses.

Legal proceedings

See Note 18 to the Consolidated Financial Statements (Part II, Item 8 of this Report) for information regarding legal proceedings in which we are involved.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Yahoo FinanceDGX quote
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
    SEC EDGAROther events
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88